<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03822559</url>
  </required_header>
  <id_info>
    <org_study_id>0111A04LT</org_study_id>
    <nct_id>NCT03822559</nct_id>
  </id_info>
  <brief_title>A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Randomized, Double-masked, Controlled Parallel Group, Multi-center Study of DE-111A (Fixed Dose Combination of Tafluprost and Timolol Eye Drops) on the Treatment of Open Angle Glaucoma or Ocular Hypertension (With Tafluprost Eye Drops as a Comparator)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santen Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate whether the IOP (intraocular pressure)
      -lowering effect of DE-111A (preservative-free fixed dose combination of 0.0015% tafluprost
      and 0.5% timolol eye drops, administered one drop a time, once daily for 3 months) is
      superior to the monotherapy of tafluprost 0.0015% eye drops administered one drop a time,
      once daily for 3 months) in subjects with open-angle glaucoma or ocular hypertension in China
      as well as comparison of safety.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the average diurnal IOP (intraocular pressure)</measure>
    <time_frame>Three months</time_frame>
    <description>Diurnal IOP measurements will be performed at 8:00 (±1 h), 10:00 (±1 h) and 16:00 (±1 h).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">324</enrollment>
  <condition>Open-angle Glaucoma, Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>DE-111A eye drops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.0015% tafluprost eye drops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL</intervention_name>
    <description>One drop a time, once daily administration of DE-111A eye drops in the affected eye(s) at 8:00 am (±1h) for 3 months.</description>
    <arm_group_label>DE-111A eye drops</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL</intervention_name>
    <description>One drop a time, once daily administration of preservative-free 0.0015% tafluprost eye drops in the affected eye(s) at 8:00 (±1h) for 3 months.</description>
    <arm_group_label>0.0015% tafluprost eye drops</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of open angle glaucoma (including primary open angle glaucoma, exfoliation
             glaucoma or pigmentary glaucoma) in one or both eyes or ocular hypertension for which
             the subject has been using prostaglandin or beta-adrenergic blocker IOP (intraocular
             pressure) -lowering drugs before the screening visit

          -  Those who have signed the informed consent form

        Exclusion Criteria:

          -  Women who are pregnant, nursing or planning pregnancy, or women of child-bearing
             potential who are not using a reliable method of contraception

          -  Anterior chamber angle in either eye to be treated with the level &lt;2 according to
             Shaffer classification as measured by gonioscopy

          -  Corneal disorder or other disease preventing reliable applanation tonometry in the
             treated eyes, including refractive surgery of ocular anterior segment)

          -  Alcohol or drug abuse

          -  Current participation in another clinical trial involving an investigational
             drug/device, or participation in such a trial within 30 days before Screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Santen Pharmaceutical Co., Ltd.</last_name>
    <phone>+81-6-4802-9338</phone>
    <email>clinical@santen.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aier Eye Hospital Group Co., Ltd Changsha Aier Eye Hospital</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinical@santen.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eye &amp; Ent Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>clinical@santen.co.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 28, 2019</study_first_submitted>
  <study_first_submitted_qc>January 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

